Anales de la RANM

59 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 TERAGNOSIS EN MEDICINA NUCLEAR José Luis Carreras Delgado An RANM · Año 2020 · número 137 (01) · páginas 54 a 59 9. Rauscher I, Düwel C, Haller B, et al. Efficacy, Pre- dictive Factors, and Prediction Nomograms for 68 Ga-labeled Prostate-specific Membrane Antigen– ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Pros- tate Cancer After Radical Prostatectomy. Eur Urol. 2018;73(5):656–661. 10. Sachpekidis C, Eder M, Kopka K, et al. 68 Ga-PS- MA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Im- aging. 2016;43(7):1288–1299. 11. Beheshti M, Manafi-Farid R, Geinitz H, et al. Multi-phasic 68 Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA < 1 ng/ml: a prospective study of 135 cases. . J Nucl Med. 2020;jnumed.119.238071. 12. Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol [Internet]. 2019; Available from: https://doi.org/10.1016/j. eururo.2019.01.049 13. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68 Ga-la- belled PSMA ligand and 18F-choline-based PET/ CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. 14. Yadav MP, Ballal S, Bal C, et al. Efficacy and Safety of 177 Lu-PSMA-617 Radioligand Therapy in Meta- static Castration-Resistant Prostate Cancer Pa- tients. Clin Nucl Med. 2020;45(1):19–31. 15. Rasul S, Hacker M, Kretschmer-Chott E, et al. Cli- nical outcome of standardized 177 Lu-PSMA-617 therapy in metastatic prostate cancer patients re- ceiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging. 2020;47(3):713–720. 16. Rathke H, Giesel FL, Flechsig P, et al. Repeated 177 Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq. J Nucl Med. 2018;59(3):459–465. 17. Hamson EJ, Keane FM, Tholen S, et al. Unders- tanding fibroblast activation protein (FAP): Substrates, activities, expression and targe- ting for cancer therapy. Proteomics Clin Appl. 2014;8(5–6):454–463. 18. Jiang GM, Xu W, Du J, et al. The application of the fibroblast activation protein a-targeted immu- notherapy strategy. Oncotarget. 2016;7(22):33472– 33482. 19. Henry LR, Lee HO, Lee JS, et al. Clinical im- plications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13(6):1736–1741. 20. Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37(2):154–158. 21. Zhang Y, Tang H, Cai J, et al. Ovarian cancer- associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting an- giogenesis, lymphangiogenesis and tumor cell in- vasion. Cancer Lett [Internet]. 2011;303(1):47– 55. Available from: http://dx.doi.org/10.1016/j. canlet.2011.01.011 22. Ju MJ, Qiu SJ, Fan J, et al. Peritumoral activated he- patic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol. 2009;131(4):498–510. 23. Loktev A, Lindner T, Mier W, et al. A tumor-imag- ing method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423–1429. 24. Lindner T, Loktev A, Altmann A, et al. Develop- ment of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–1422. 25. Welt S, Divgi CR, Scott AM, et al. Antibody tar- geting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 1994;12(6):1193–1203. 26. Giesel FL, Kratochwil C, Lindner T, et al. 68 Ga- FAPI PET/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP- targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386–392. 27. Tillmanns J, Hoffmann D, Habbaba Y, et al. Fibro- blast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol [Internet]. 2015;87:194–203. Available from: http://dx.doi.org/10.1016/j. yjmcc.2015.08.016 Si desea citar nuestro artículo: Carreras-Delgado J. L. Teragnosis en medicina nuclear ANALES RANM [Internet]. Real Academia Nacional de Medicina de España; An RANM · Año 2020 · número 137 (01) · páginas 54–59 DOI: 10.32440/ar.2020.137.01.rev06 DECLARACIÓN DE TRANSPARENCIA El autor/a de este artículo declara no tener ningún tipo de conflicto de intereses respecto a lo expuesto en la presente revisión.